Multicentric Randomized Phase I/II Study to Evaluate Efficacy of Trifluridine/Tipiracil Plus XB2001 (Anti-IL-1α True Human Antibody) Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine
Latest Information Update: 04 Jun 2025
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Vilamakitug (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TASKIN
Most Recent Events
- 30 May 2025 Status changed from recruiting to active, no longer recruiting.
- 12 Feb 2024 Planned End Date changed from 1 Mar 2026 to 13 Oct 2026.
- 12 Feb 2024 Planned primary completion date changed from 1 Mar 2024 to 13 Oct 2026.